The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Secondary Infections

Secondary Infections

Secondary infections refer to infections that occur as a complication or consequence of an initial primary infection.
These infections can be caused by different pathogens and may arise due to weakened immune systems, disrupted natural barriers, or the spread of the initial infection.
Identifying and managing secondary infections is crucial for patient care, as they can lead to more severe illness, increased risk of complications, and prolonged recovery times.
Understanding the mechanisms, risk factors, and appropriate treatment strategies for secondary infections is an important area of research to improve clinical outcomes and enhance the quality of patient care.

Most cited protocols related to «Secondary Infections»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Activated Partial Thromboplastin Time Axilla Bacteremia Blood Blood Coagulation Disorders Bronchoalveolar Lavage Fluid Chinese Congenital Abnormality COVID 19 Echocardiography Electrocardiography Fever Heart Heart Injuries Hospital Administration Hypersensitivity Hypoproteinemia Kidney Injury, Acute pathogenesis Patients Pneumonia Pneumonia, Ventilator-Associated Respiratory Distress Syndrome, Acute Respiratory System Seafood Secondary Infections Septicemia Septic Shock Serum Albumin Sputum Times, Prothrombin Troponin I

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Bacteremia Blood Bronchoalveolar Lavage Fluid Congenital Abnormality Creatinine Echocardiography Electrocardiography Heart Heart Injuries Influenza in Birds Inhalation Kidney Diseases Kidney Injury, Acute Oxygen pathogenesis Patients Pneumonia, Hospital Acquired Respiratory Distress Syndrome, Acute Respiratory System SARS-CoV-2 Secondary Infections Serum Shock Sputum Troponin I Urine

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
COVID 19 Households Maritally Unattached Population at Risk Reproduction Secondary Infections Transmission, Communicable Disease
Details of the epidemic, including clinical and laboratory findings for all patients, will be reported elsewhere (M.R. Duffy et al., unpub. data). A subset of ZIKV-infected patients for whom acute- and convalescent-phase paired serum specimens had been collected was analyzed by using several serologic assays to evaluate the extent of cross-reactivity to several related flaviviruses. Patients were classified as primary flavivirus/ZIKV infected or secondary flavivirus/ZIKV probable infected. Primary flavivirus/ZIKV–infected patients were those in whom acute-phase serum specimens (<10 days) had no detectible antibodies (by IgG ELISA and plaque-reduction neutralization test [PRNT]) to any of the heterologous flaviviruses tested (Tables 1, 2) and were either IgM-positive in their acute-phase specimen or IgM and IgG positive for ZIKV in a convalescent-phase specimen (seroconversion). Secondary flavivirus/ZIKV probable–infected patients were those who had detectable antibodies to >1 heterologous flaviviruses in their acute-phase specimen and were also IgM positive for ZIKV in their acute-phase specimen, or IgM and IgG positive for ZIKV in their convalescent-phase specimen. The designation “ZIKV probable” was used because secondary flavivirus infections demonstrate extensive cross-reactivity with other flaviviruses, and in some cases, higher serologic reactivity to the original infecting flavivirus (“original antigenic sin” phenomenon). Thus, in secondary flavivirus infections shown in Tables 1 and 2, serologic data alone is insufficient to confirm ZIKV as the recently infecting flavivirus. However, these secondary flavivirus/ZIKV probable infections were likely recent ZIKV infections because ZIKV was the only virus detected during the epidemic in Yap, a relatively small and isolated island (11 ).
Full text: Click here
Publication 2008
Antibodies Antigens Biological Assay Cross Reactions Enzyme-Linked Immunosorbent Assay Epidemics Flavivirus Flavivirus Infections Patch Tests Patients Secondary Infections Serum Virus Zika Virus Zika Virus Infection
In the model, we divided individuals into four infection classes, as follows: susceptible, exposed (but not yet infectious), infectious, and removed (ie, isolated, recovered, or otherwise no longer infectious; figure 1). The model accounted for delays in symptom onset and reporting by including compartments to reflect transitions between reporting states and disease states. The model also incorporated uncertainty in case observation, by explicitly modelling a Poisson observed process of newly symptomatic cases, reported onsets of new cases, reported confirmation of cases, and a binomial observation process for infection prevalence on evacuation flights (appendix pp 1–3). The incubation period was assumed to be Erlang distributed with mean 5·2 days14 (link) (SD 3·7) and delay from onset to isolation was assumed to be Erlang distributed with mean 2·9 days (2·1).2 , 15 (link) The delay from onset to reporting was assumed to be exponentially distributed with mean 6·1 days (2·5).2 Once exposed to infection, a proportion of individuals travelled internationally and we assumed that the probability of cases being exported from Wuhan to a specific other country depended on the number of cases in Wuhan, the number of outbound travellers (assumed to be 3300 per day before travel restrictions were introduced on Jan 23, 2020, and zero after), the relative connectivity of different countries,16 and the relative probability of reporting a case outside Wuhan, to account for differences in clinical case definition, detection, and reporting within Wuhan and internationally. We considered the 20 countries outside China most at risk of exported cases in the analysis.

Model structure

The population is divided into the following four classes: susceptible, exposed (and not yet symptomatic), infectious (and symptomatic), and removed (ie, isolated, recovered, or otherwise non-infectious). A fraction of exposed individuals subsequently travel and are eventually detected in their destination country.

We modelled transmission as a geometric random walk process, and we used sequential Monte Carlo simulation to infer the transmission rate over time, as well as the resulting number of cases and the time-varying basic reproduction number (Rt), defined here as the mean number of secondary cases generated by a typical infectious individual on each day in a full susceptible population. The model had three unknown parameters, which we estimated: magnitude of temporal variability in transmission, proportion of cases that would eventually be detectable, and relative probability of reporting a confirmed case within Wuhan compared with an internationally exported case that originated in Wuhan. We assumed the outbreak started with a single infectious case on Nov 22, 2019, and the entire population was initially susceptible. Once we had estimated Rt, we used a branching process with a negative binomial offspring distribution to calculate the probability an introduced case would cause a large outbreak. We also did a sensitivity analysis on the following three key assumptions: we assumed the initial number of cases was ten rather than one; we assumed connectivity between countries followed WorldPop rather than MOBS Lab estimates; and we assumed that cases were infectious during the second half of their incubation period rather than only being infectious while symptomatic. All data and code required to reproduce the analysis is available online.
Full text: Click here
Publication 2020
Hypersensitivity Infection isolation Secondary Infections Transmission, Communicable Disease

Most recents protocols related to «Secondary Infections»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Adrenal Cortex Hormones Antiviral Agents Biological Evolution Chest Clinical Investigators Hematologic Tests Intravenous Infusion Nasopharynx Oxygen Patients Physical Examination remdesivir Respiratory Rate Safety sarilumab SARS-CoV-2 Secondary Infections Signs, Vital Therapeutics X-Ray Computed Tomography X-Rays, Diagnostic
The model used a 1 month time horizon. Specifically, for each border-opening policy, we predicted the numbers of vaccinated and unvaccinated, inbound and returning travelers within a month. For each subgroup of travelers, all imported cases among them and all secondary cases caused by them were counted, recoveries and secondary infections beyond 1 month included.
Full text: Click here
Publication 2023
Secondary Infections
The meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA—http://prisma-statement.org/PRISMAStatement/PRISMAStatement.aspx) reporting guidance, and it was registered in the International Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42021253185).
The following PICO (patients, intervention, comparison, outcome) format was applied: P: PCR confirmed COVID-19 infected patients; I: ivermectin alone or in combination with standard care or in combination with other drugs; C: standard care or therapy without ivermectin; and O: days required for viral clearance.
For the purpose of continued information of the field, we also include a scoping review activity of ivermectin-related publications on clinical trial results up to 31 Oct 2022, when the formalization of our manuscript was finished. Study reports were retrieved in English in this case, using ClinicalTrials.gov, Google Scholar, and PubMed and searching for ivermectin application reports in clinical trials with emphasis on relevance to our original PICO: early application, mild-moderate disease, and viral clearance. We include the results of this overview outside the formal results reporting, in Table 4. in the “Discussion” part.

Characteristics of the studies included in the quantitative analysis

StudyCountryDesignP (patients)I (intervention)C (comparator)O (outcome)
Khan [29 (link)]BangladeshRetrospective, cohort

PCR confirmed COVID-19 patients

(n = 248)

12-mg ivermectin (single dose) plus standard careStandard care (as required and included antipyretics for fever, anti-histamines for cough, and antibiotics to control secondary infection)

- Time required for virological clearance

- Disease progression (develop pneumonia to severe respiratory distress)

- Duration of hospital stays, and

- Mortality rate

Ahmed [28 (link)]Bangladeshdouble-blinded randomized controlled trialHospitalized COVID-19 patients (n = 72)Group A: 12-mg ivermectin daily for 5 days

Group B: 12-mg ivermectin and 200-mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days)

Group C: placebo

Primary endpoints:

- Time required for virological clearance

- Remission of fever and cough within 7 days

Secondary outcomes:

- Failure to maintain an SpO2 > 93% despite oxygenation

- Days on oxygen support

- The duration of hospitalization

- All-cause mortality

Babalola [27 (link)]Nigeriadouble-blinded randomized controlled trialPCR-proven COVID-19 positive patients (n = 62)

Group A: Standard care plus ivermectin 6 mg every 84 h, twice a week, for 2 weeks

Group B: Standard care plus ivermectin 12 mg every 84 h, twice a week, for 2 weeks

Group C: Standard care plus lopinavir/ritonavir daily for 2 weeks- Time required for virological clearance
Full text: Click here
Publication 2023
Antibiotics Antipyretics Cell Respiration Cough COVID 19 Disease Progression Doxycycline Fever Histamine Antagonists Hospitalization Ivermectin lopinavir-ritonavir drug combination Oxygen Patients Pharmaceutical Preparations prisma Saturation of Peripheral Oxygen Secondary Infections Therapeutics
This was a retrospective study approved by the Institutional Review Board of The First Affiliated Hospital of Soochow University, and informed consent was obtained from all patients.
Between January 2019 to December 2020, 223 patients (185 females and 38 males) who were diagnosed as single level OVF and treated by PKP surgery in our institution were included in this study. The included patients were classified into two groups according to the presence or absence of fascia injury (With-FI group and Without-FI group). The average age of the patients was 70.35 ± 8.34 years (ranging from 55 to 93 years).
Inclusion criteria: 1) bone marrow edema in the affected vertebra with or without posterior fascia injury in MR images; 2) severe back pain unresponsive to conservative treatment for at least one week; 3) T-scores assessed by Dual Energy X-ray Absorptiometry was less than -2.5.
Exclusion criteria: 1) pathological fracture secondary to infection or malignancy; 2) unable to tolerate the operation; 3) severe OVF presented fracture dislocation; 4) neurological deficit caused by OVF; 5) combined with Alzheimer's disease or other diseases which made the patients unable to finish information collection on their own.
The time interval between fracture and PKP surgery was recorded as fracture age. The OVF related trauma history was evaluated and the severity of trauma was divided into three degrees (none or minor, moderate, and severe). Vertebral fractures caused by coughing, twisting waist, and other daily activities were considered minor trauma. Moderate trauma was defined as stumble, falls from chairs, and other minor accidents caused by definite external forces. Serious trauma was referred to car accidents, falls from high places and other damages caused by severe external forces.
Full text: Click here
Publication 2023
Accidents Alzheimer's Disease Back Pain Bone Marrow Conservative Treatment Dual-Energy X-Ray Absorptiometry Edema Ethics Committees, Research Fascia Females Fracture, Bone Fracture Dislocation Injuries Males Malignant Neoplasms Marrow Operative Surgical Procedures Pathological Fracture Patients Secondary Infections Spinal Fractures Vertebra Wounds and Injuries
The data of 118 children with primary focal segmental glomerulosclerosis admitted to the Nursing Department of West China Second Hospital from January 2012 to January 2017 were retrospectively collected. The children were divided into a hypertension group (n=48) and a control group (n=70) according to whether they had hypertension, and were followed up for 5 years to compare the difference in prognosis between the two groups. The inclusion criteria were as follows: (I) primary focal segmental glomerulosclerosis diagnosed by renal biopsy; (II) aged 3–17 years; and (III) complete clinical medical records. The exclusion criteria were as follows: (I) lost to follow-up; (II) secondary infection; (III) malignant tumor; (IV) solitary kidney; (V) diabetes nephropathy, immunoglobulin A nephropathy, membranous nephropathy, lupus nephritis, purpura nephritis, and other nephropathies; (VI) secondary focal segmental glomerulosclerosis; and (VII) cases in which end-stage renal disease had been diagnosed. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of the Nursing Department of West China Second Hospital (No. 2022KY-0098), and the requirement for the patients’ written informed consent for this retrospective clinical study was waived.
Publication 2023
Biopsy Child Diabetic Nephropathy Ethics Committees, Clinical Glomerulosclerosis, Focal High Blood Pressures IGA Glomerulonephritis Kidney Kidney Diseases Kidney Failure, Chronic Lupus Nephritis Malignant Neoplasms Membranous Glomerulonephritis Nephritis Patients Prognosis Purpura Renal Agenesis, Unilateral Secondary Infections

Top products related to «Secondary Infections»

Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, Macao, Canada, France, Japan, Switzerland, Italy, Australia, Netherlands, Morocco, Israel, Ireland, Belgium, Denmark, Norway
Polybrene is a cationic polymer used as a transfection reagent in cell biology research. It facilitates the introduction of genetic material into cells by enhancing the efficiency of DNA or RNA uptake.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, Macao, Canada, Japan, Italy, Switzerland, France, Israel, Australia, Spain, Belgium, Morocco, Sweden
Puromycin is a laboratory product manufactured by Merck Group. It functions as an antibiotic that inhibits protein synthesis in eukaryotic cells.
Sourced in United States, Switzerland, China, Japan, Germany, United Kingdom, France, Canada
PsPAX2 is a packaging plasmid used for the production of lentiviral particles. It contains the necessary genes for lentiviral packaging, but does not contain the viral genome. PsPAX2 is commonly used in lentiviral production workflows.
Sourced in United States, Switzerland, China, Germany, France, Japan, United Kingdom, Canada
The PMD2.G is a lab equipment product. It is a plasmid that can be used for various research applications.
Sourced in United States, Germany, China, United Kingdom, Canada, France, Japan, Switzerland, Holy See (Vatican City State), Israel
HEK293T cells are a widely used human embryonic kidney cell line. They are derived from human embryonic kidney cells transformed with sheared adenovirus 5 DNA. HEK293T cells are commonly used for a variety of applications, including gene expression, viral production, and cell-based assays.
Sourced in United States, Australia
The Panbio Dengue IgM Capture ELISA is a laboratory diagnostic test used to detect the presence of dengue virus-specific immunoglobulin M (IgM) antibodies in human serum or plasma samples. It is designed to aid in the diagnosis of acute dengue virus infection.
Sourced in Japan, United States, France, Denmark, China
RetroNectin is a recombinant human fibronectin fragment that promotes efficient retroviral transduction. It facilitates the binding of retroviral particles to target cells, thereby enhancing the efficiency of gene delivery.
Sourced in United States, Germany, Macao, Canada
Hexadimethrine bromide is a cationic polymer used as a laboratory reagent. It is a chemical compound with the molecular formula (C10H22N2)nBr. The primary function of hexadimethrine bromide is to serve as a transfection agent, facilitating the introduction of genetic material into cells.
Sourced in France
The Dengue NS1 Ag STRIP is a rapid diagnostic test designed to detect the Dengue virus non-structural protein 1 (NS1) antigen in human serum, plasma, or whole blood samples. The test is intended to aid in the diagnosis of acute dengue infection.

More about "Secondary Infections"

Secondary infections, also known as superinfections or complicating infections, refer to infections that occur as a consequence or complication of an initial primary infection.
These subsequent infections can be caused by different pathogens and may arise due to factors such as weakened immune systems, disruption of natural barriers, or the spread of the original infection.
Identifying and managing secondary infections is crucial for effective patient care, as they can lead to more severe illness, increased risk of complications, and prolonged recovery times.
Understanding the underlying mechanisms, risk factors, and appropriate treatment strategies for secondary infections is an important area of research to improve clinical outcomes and enhance the quality of patient care.
Related terms and concepts include co-infections, nosocomial infections, opportunistic infections, and polymicrobial infections.
Key subtopics involve the epidemiology, pathogenesis, diagnosis, and management of secondary infections, as well as the role of various laboratory techniques and reagents like Polybrene, Lipofectamine 2000, Puromycin, PsPAX2, PMD2.G, HEK293T cells, Panbio Dengue IgM Capture ELISA, RetroNectin, and Hexadimethrine bromide in secondary infection research and treatment.
For example, Polybrene (also known as Hexadimethrine bromide) is a cationic polymer that can enhance the efficiency of viral transduction, which is relevant for studying the mechanisms of secondary viral infections.
Lipofectamine 2000 is a transfection reagent used to introduce genetic material into cells, aiding in the investigation of host-pathogen interactions.
Puromycin, PsPAX2, and PMD2.G are all tools utilized in lentiviral vector production, which can be employed to model secondary infections.
HEK293T cells are commonly used as a cell line for viral propagation and infection studies.
Panbio Dengue IgM Capture ELISA and Dengue NS1 Ag STRIP are diagnostic tests that can be used to identify secondary dengue infections.
RetroNectin is a recombinant fibronectin fragment that can enhance the efficiency of retroviral transduction, relevant for studying secondary viral infections.